Government
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 29, 2020.
The U.S. Food and Drug Administration approved an additional recommended dosage of 400 mg every six weeks for the anti-PD-1 therapy across all adult indications, including as a monotherapy and in combination treatments.
Neurocrine Biosciences announced on Monday that it has received approval from the U.S. Food and Drug Administration for its once-daily oral drug, Ongentys, as an add-on treatment to levodopa/carbidopa for the treatment of Parkinson’s disease.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
Here is a cross-section of some of the surveys about the COVID-19 pandemic over the last few weeks.
Many of the tests that are available are giving false-positives, which means that some people who have not been exposed to COVID-19 are under the impression they have been.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 27, 2020.
Gilead Sciences filed a lawsuit against the United States government alleging the U.S. Centers for Disease Control and Prevention violated a contract that governed an HIV research collaboration between the company and government agency.
David Loew, head of Sanofi Pasteur, said U.S. approval of the vaccine is an important milestone in the fight against meningococcal meningitis, a serious global health challenge that can be fatal within 24 hours.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 24, 2020.
PRESS RELEASES